By Josh Beckerman


Amgen Inc. agreed to buy biotechnology company Teneobio for a $900 million upfront cash payment, plus future contingent milestone payments potentially valued at up to an additional $1.6 billion.

Teneobio is developing biologics called human heavy-chain antibodies. The company's multi-specific antibodies "engage the immune system against multiple disease types, including cancer, autoimmune disorders and infectious diseases." Its antibody discovery platform is based on UniRat, a "proprietary heavy-chain only, human immunoglobulin transgenic rat."

Amgen said Teneobio's technology "will enable significant acceleration and efficiency in the discovery and development of new molecules," and its T-cell engager platform "expands on Amgen's existing leadership position in bispecific T-cell engagers."

In June, AbbVie Inc. exercised its right to acquire TeneoOne Inc., a Teneobio affiliate. Teneobio's investors have include Lightspeed Venture Partners.


Write to Josh Beckerman at


(END) Dow Jones Newswires

July 27, 2021 19:15 ET (23:15 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Amgen Charts.
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Amgen Charts.